Introducing DiaSorin acquisition of Focus Diagnostics
On the 13th of May 2016, DiaSorin (FTSE Italy: DIA) and Quest Diagnostics (NYSE: DGX) have closed a purchase agreement under which DiaSorin has bought Quest's Focus Diagnostics, Inc. immunodiagnostic and molecular diagnostic products business ("Focus").
Purchase agreement terms
DiaSorin has acquired all the tangible and intangible assets to develop, manufacture and distribute Focus molecular diagnostic and traditional immunoassay ELISA products. Current contracts and customer lists are also included in the deal.
The acquisition does not include Quest's diagnostic information service laboratories, currently operating under the Focus Diagnostics brand, which will continue to be part of Quest.
DiaSorin expects to continue to manufacture Focus products from the company's base facility in Cypress, California, USA.
Download the press release
All the contents and service will move on diasorin.com website in the next weeks.
For additional information on the press release, please contact for DiaSorin:
Riccardo Fava - Investor Relations & Corporate Communication Senior Director
+39 0161 487.988